NR vs NMN: Comparing Human Studies Without Promising Anti-Aging Results

Human trials do not currently support a simple claim that NR or NMN is the “better anti-aging precursor.” Both nicotinamide riboside, abbreviated NR, and nicotinamide mononucleotide, abbreviated NMN, participate in NAD-related metabolism. Trials have shown that selected oral preparations can raise NAD or related metabolites in blood or tissue. Functional outcomes are more mixed, and the two ingredients have rarely been compared under the same protocol.

That distinction matters for Granver. NAD+ Supreme Rejuvenation currently lists NMNH, the reduced form of NMN, inside a proprietary complex. It does not list NR or NMN as the named product ingredient. NR and NMN studies therefore provide background on NAD-precursor research, not clinical evidence for that product or for NMNH.

Biomarker change and benefit are separate questions

NAD is involved in cellular redox reactions and serves as a substrate for several enzyme systems. Measuring more NAD or a related metabolite after supplementation can help establish biological availability. It does not, by itself, prove improved energy, cognition, sleep, skin appearance, disease risk, or lifespan.

A useful evidence review separates three levels:

1. Exposure: Did the compound or its metabolites appear in the body?
2. Target engagement: Did NAD or a related biochemical measure change in the sampled tissue?
3. Functional outcome: Did a prespecified measure of health or performance improve relative to placebo?

Marketing often jumps from level two to level three. Human trials show why that jump is unsafe: a biomarker can move while several clinical or physiological endpoints do not.

Four trials illustrate the evidence landscape

These are not head-to-head trials. The doses, participants, durations, tissues, assays, and outcomes differ. Reading across rows can show what has been studied; it cannot produce a valid winner.

What selected NR trials found

In a randomized crossover trial, Martens and colleagues studied healthy adults aged roughly 55 to 79. Six weeks of NR at 500 mg twice daily increased blood NAD-related measures and was generally well tolerated during the study. The paper also reported exploratory signals in blood pressure and arterial stiffness that the authors said required further testing. Read the trial.

The design is useful for showing target engagement over several weeks, but the sample was small and the physiological findings were not proof of disease prevention. The study acknowledged public funding and partial funding from ChromaDex, which also supplied the study pills and NR standards. The authors declared no competing interests.

A separate 12-week trial tested a higher total amount, 2,000 mg daily, in 40 men with obesity and insulin resistance. It found no improvement in insulin sensitivity, endogenous glucose production, glucose disposal or oxidation, resting energy expenditure, lipid oxidation, or body composition. No serious adverse events attributed to NR were reported. Read the negative metabolic trial.

That result does not prove NR has no possible use. It does prevent a biomarker or animal finding from being described as guaranteed metabolic improvement in people. The trial received independent Danish research funding, while the study material was donated by ChromaDex.

What selected NMN trials found

Yoshino and colleagues enrolled 25 postmenopausal women with prediabetes who had overweight or obesity. Participants received 250 mg of NMN daily or placebo for 10 weeks. The NMN group showed improved insulin-stimulated muscle glucose disposal and selected muscle-signaling measures. Several broader outcomes, including body weight and fasting glucose, did not change. Read the trial.

This is a meaningful human result in a carefully defined group, not a universal anti-aging result. It cannot be assumed to apply to men, younger adults, metabolically healthy people, other doses, or other formulations. The study had public and nonprofit support; the NMN and placebo were supplied by Oriental Yeast Co.

Another randomized trial assigned 30 healthy Japanese adults to 250 mg of NMN daily or placebo for 12 weeks. Whole-blood NAD increased, and the paper focused mainly on safety and laboratory observations. It did not establish a broad improvement in aging, disease risk, or daily function. Mitsubishi Corporation Life Sciences manufactured and supplied the study tablets. Read the full trial.

These NMN studies also differ from each other in population and goals. One tested a metabolic endpoint in a narrow group; the other emphasized safety and NAD measurements in healthy volunteers. Their positive findings should remain attached to those designs.

Why cross-trial ranking fails

Several common shortcuts create a false comparison:

• Comparing milligrams directly. Equal mass does not mean equal molar exposure, purity, stability, absorption, or target engagement.
• Comparing different specimens. Whole-blood NAD, muscle metabolites, and circulating related compounds are not interchangeable measures.
• Ignoring the population. A result in postmenopausal women with prediabetes cannot be treated as the expected response of every adult.
• Counting only positive endpoints. Trials often measure many outcomes. A credible summary includes prespecified primary outcomes and null results.
• Treating duration as anti-aging proof. Six to twelve weeks can assess short-term exposure and selected functions, but not human lifespan or long-term disease prevention.
• Combining unrelated products. Ingredient preparation, purity, dose, and co-ingredients matter. Finished formulas need their own evidence.

Our NAD and healthy-aging guide provides the broader biology. The NMNH versus NMN explainer covers the chemical distinction between the oxidized and reduced mononucleotide forms. Neither source turns NR or NMN trials into evidence for NMNH.

How to compare a product with the research

Start with the label, not a generational marketing term. Record the exact compound, salt or form, amount per serving, purity or specification, serving directions, and other ingredients. Then match the study's preparation, dose, duration, population, comparator, and endpoint.

NAD+ Supreme Rejuvenation's current Supplement Facts lists a 220 mg Proprietary Rejuvenation Complex containing NMNH, L-ergothioneine, ginseng extract, and grape phenolic complex. Because the complex contains several ingredients, the NMNH amount is not disclosed. The formula also has a separate 180 mg proprietary complex. These facts prevent a dose match to an NR or NMN trial.

The current NAD+ Supreme Rejuvenation page can establish what the product lists. It cannot establish that the finished formula reproduces any trial in the table. Granver's ingredient-quality and evidence checklist offers questions to ask before comparing supplier research with a finished product.

Safety evidence has a time horizon

“Well tolerated” means no major safety problem emerged under a particular study's dose, population, duration, and monitoring. It does not mean zero risk for every person or indefinite use. Short trials can miss uncommon events and cannot resolve long-term safety.

People who are pregnant or breastfeeding, are receiving cancer treatment, have a medical condition, or take medication should discuss NAD-precursor supplements with a qualified clinician. Do not use an NAD biomarker as a reason to change treatment or assume that more capsules will produce a greater functional benefit.

The NIH dietary supplement overview explains why supplement use should be evaluated with health conditions and medications in mind. For any product, keep the current label and adverse-event information available to the clinician.

FAQs

Your next step

Review the NAD+ Supreme Rejuvenation label information, then use the exposure, target-engagement, and functional-outcome framework to evaluate any cited study. For a general buying approach, see the healthy-aging supplement guide.

Educational information only. Granver products are dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This article does not replace individualized nutrition or medical care.